Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03456336 · ClinicalTrials.gov registry record · Phase 3
Management of the PDA Trial
A Phase 3 study of Infant, Premature and Infant, Newborn, Diseases, sponsored by NICHD Neonatal Research Network.
- Active
- Registry status
- Phase 3
- Development phase
- 836
- Enrollment target
- 19
- Study locations
NCT03456336 is a Phase 3 study of Infant, Premature and Infant, Newborn, Diseases that is active but no longer recruiting, run by NICHD Neonatal Research Network. The registered enrollment target is 836 participants, below the 11,234-participant average among 14 other Infant, Premature trials with a reported enrollment target (93% lower). The trial reports 19 study locations across 14 states.
The verdict
NCT03456336, a Phase 3 study of Infant, Premature and Infant, Newborn, Diseases, is active but no longer recruiting, sponsored by NICHD Neonatal Research Network.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 836 participants
- Enrollment target
- 19
- Study locations
Study Summary
Estimate the risks and benefits of active treatment versus expectant management of a symptomatic patent ductus arteriosus (sPDA) in premature infants.
Conditions Studied
Interventions
- OTHER Active Treatment
- OTHER Expectant Management
Study Locations (19)
Ohio
- Cincinnati Children's Medical Center - Cincinnati
- Case Western Reserve University, Rainbow Babies and Children's Hospital - Cleveland
- Research Institute at Nationwide Children's Hospital - Columbus
California
- Stanford University - Palo Alto
- Sharp Mary Birch Hospital for Women & Newborns - San Diego
North Carolina
- RTI International - Durham
- Duke University - Durham
Texas
- University of Texas Southwestern Medical Center at Dallas - Dallas
- University of Texas Health Science Center at Houston - Houston
Alabama
- University of Alabama at Birmingham - Birmingham
Georgia
- Emory University - Atlanta
Illinois
- Northwestern Lurie Children's Hospital of Chicago - Chicago
Iowa
- University of Iowa - Iowa City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 836 participants |
| Start Date | 2019-02-22 |
| Est. Completion | 2027-05-30 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03456336
The ClinicalTrials.gov registry entry for NCT03456336 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 836 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 11,234-participant average among 14 other Infant, Premature trials with a reported enrollment target (93% lower). The listed sponsor is NICHD Neonatal Research Network, which has 61 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Infant, Premature appearing as the primary indexed condition, and to 2 interventions - of which Active Treatment is the first listed.
NCT03456336 reports 19 study locations spanning 14 distinct geographic areas - top geographies include Ohio, California, North Carolina.
Frequently Asked Questions
What is clinical trial NCT03456336 about?
NCT03456336 is a clinical study titled "Management of the PDA Trial". Estimate the risks and benefits of active treatment versus expectant management of a symptomatic patent ductus arteriosus (sPDA) in premature infants.
What is the current status of trial NCT03456336?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 836 participants. The study started on 2019-02-22. Estimated completion is 2027-05-30.
What conditions does trial NCT03456336 study?
This clinical trial studies the following conditions: Infant, Premature, Infant, Newborn, Diseases, Patent Ductus Arteriosus, Patent Ductus Arteriosus After Premature Birth.
What interventions are being tested in trial NCT03456336?
The interventions under investigation include: Active Treatment (OTHER), Expectant Management (OTHER).
Who is sponsoring clinical trial NCT03456336?
This trial is sponsored by NICHD Neonatal Research Network, which has 61 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03456336 being conducted?
This trial has 19 study locations across Alabama, California, Georgia, Illinois, Iowa. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Infant, Premature
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Hydrocortisone for BPD
COMPLETED · Phase 3
-
Glutamine Supplementation to Prevent Death or Infection in Extremely Premature Infants
COMPLETED · Phase 3
-
Generic Database of Very Low Birth Weight Infants
RECRUITING
-
Follow-up Visit of High Risk Infants
RECRUITING
-
Cerebral Function Monitoring in Premature Infants
COMPLETED
-
Intravenous Immune Globulin (IVIG) to Prevent Neonatal Infection
COMPLETED · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.